Trial site
St John of God Murdoch Hospital
Murdoch, Western Australia 6150, AustraliaNot linked to an institution yet
- 12running trials
- 5closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 2/35 trials
- Phase 22 trials
- Phase 1/21 trial
- Status
- Active, not recruiting6 trials
- Recruiting6 trials
- Completed4 trials
- Terminated1 trial
- Lead sponsor
- Bristol-Myers Squibb4 trials
- Amgen2 trials
- Regeneron Pharmaceuticals2 trials
- Australian and New Zealand Intensive Care Research Centre1 trial
- AVEO Pharmaceuticals, Inc.1 trial
- and 7 more
Running trials
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Kynan Feeney, Site 0083
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177· Phase 2· Genmab· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Kynan Feeney, Site 0154
Active, not recruiting
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: Kynan Feeney, Site 0056
Active, not recruiting
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877· Phase 3· AVEO Pharmaceuticals, Inc.· Source
Contact: Clinical Trials Office
Active, not recruiting
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT05800015· Phase 2/3· Regeneron Pharmaceuticals· Source
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171· Phase 2/3· Panbela Therapeutics, Inc.· Source
Contact: Rebecca Weselman
Active, not recruiting
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
NCT04569942· Phase 3· Australian and New Zealand Intensive Care Research Centre· Source
Active, not recruiting
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT03562637· Phase 3· OBI Pharma, Inc· Source
Active, not recruiting
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error